Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0PY1G
|
|||
Drug Name |
Hydrazide derivative 3
|
|||
Synonyms |
PMID28117607-Compound-23
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
ELAN PHARMACEUTICALS, LLC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C14H9ClFN3O2S2
|
|||
Canonical SMILES |
C1C(=O)N(C(=NNC(=O)C2=CC=C(S2)Cl)S1)C3=CC=C(C=C3)F
|
|||
InChI |
1S/C14H9ClFN3O2S2/c15-11-6-5-10(23-11)13(21)17-18-14-19(12(20)7-22-14)9-3-1-8(16)2-4-9/h1-6H,7H2,(H,17,21)/b18-14+
|
|||
InChIKey |
SDAYOLNMRBBFQH-NBVRZTHBSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Leucine-rich repeat kinase 2 (LRRK2) | Target Info | Inhibitor | [1] |
Target's Patent Info | Leucine-rich repeat kinase 2 (LRRK2) | Target's Patent Info | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.